Trade Mark Journal No.2025/048 28 November 2025

UK00004297291 19 November 2025 (5)

REGENERON

International priority date claimed: 23 May 2025 (United States of America) (99199652)

Class 5: Genetically modified cells, genome editing reagents, and biological preparations, namely, viral vectors, all for the treatment and/or prevention of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer.

Regeneron Pharmaceuticals, Inc.

Representative: Appleyard Lees IP LLP